Clinical trials: Borderline Personality Disorder
Borderline Personality Disorder
Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)
Participants will be randomized to either Mifepristone 600mg once daily for seven days or Placebo tablet once daily for seven days. Rating scales, vital signs, cortisol levels will be collected for evaluation.
- Trial name
- NCT01212588
- Testing
- mifepristone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Indiana University
Borderline Personality Disorder
A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder
There are currently no pharmacological treatments approved to treat borderline personality disorder (BPD). This trial will be conducted to evaluate the efficacy and safety of brexpiprazole for the treatment of participants…
- Trial name
- NCT04100096
- Testing
- Brexpiprazole
- Where
- 77 sites in United States, Spain and 1 more
- Volunteers
- 332 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Borderline Personality Disorder, Emotional Problem
Preschooler Emotion Regulation in the Context of Maternal Borderline Personality Disorder
Offspring of mothers with Borderline Personality Disorder (BPD) are at serious risk for developing mental illness at every stage of their life, and yet little is known about how this risk is transmitted.
- Trial name
- NCT03060902
- Testing
- Dialectical Behavior Therapy Skills
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- University of Oregon
Borderline Personality Disorder
Brexpiprazole in Borderline Personality Disorder
The primary objective of the proposed study is to evaluate the safety and efficacy of Brexpiprazole in adults with borderline personality disorder (BPD).
- Trial name
- NCT03418675
- Testing
- Rexulti
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Chicago